2,6-Bis(2-Benzimidazolyl)Pyridine (BBP) Is a Potent and Selective Inhibitor of Small Conductance Calcium-Activated Potassium (SK) Channels by Simó-Vicens, Rafel et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
2,6-Bis(2-Benzimidazolyl)Pyridine (BBP) Is a Potent and Selective Inhibitor of Small
Conductance Calcium-Activated Potassium (SK) Channels








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Simó-Vicens, R., Bomholtz, S. H., Sørensen, U. S., & Bentzen, B. H. (2018). 2,6-Bis(2-Benzimidazolyl)Pyridine
(BBP) Is a Potent and Selective Inhibitor of Small Conductance Calcium-Activated Potassium (SK) Channels.
Frontiers in Pharmacology, 9, [1409]. https://doi.org/10.3389/fphar.2018.01409
Download date: 03. Feb. 2020
ORIGINAL RESEARCH
published: 03 December 2018
doi: 10.3389/fphar.2018.01409
Frontiers in Pharmacology | www.frontiersin.org 1 December 2018 | Volume 9 | Article 1409
Edited by:
Joerg Striessnig,
University of Innsbruck, Austria
Reviewed by:
Emilio Carbone,
Università degli Studi di Torino, Italy
Heike Wulff,






This article was submitted to
Pharmacology of Ion Channels and
Channelopathies,
a section of the journal
Frontiers in Pharmacology
Received: 10 September 2018
Accepted: 16 November 2018
Published: 03 December 2018
Citation:
Simó-Vicens R, Bomholtz SH,
Sørensen US and Bentzen BH (2018)
2,6-Bis(2-Benzimidazolyl)Pyridine
(BBP) Is a Potent and Selective
Inhibitor of Small Conductance
Calcium-Activated Potassium (SK)
Channels. Front. Pharmacol. 9:1409.
doi: 10.3389/fphar.2018.01409
2,6-Bis(2-Benzimidazolyl)Pyridine
(BBP) Is a Potent and Selective
Inhibitor of Small Conductance
Calcium-Activated Potassium (SK)
Channels
Rafel Simó-Vicens 1,2, Sofia H. Bomholtz 1,2, Ulrik S. Sørensen 2 and Bo H. Bentzen 1,2*
1Cardiovascular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of
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A variety of polycyclic pyridines have been proposed as inhibitors of the small
conductance calcium-activated potassium (SK) channel. To this group belongs
2,6-bis(2-benzimidazolyl)pyridine (BBP), a commercially and readily available small
organic compound which has earlier been described in a broad range of chemical and
biological uses. Here, we show how BBP can also be used as a potent and specific
SK channel blocker in vitro. The potency of BBP was measured using automatic patch
clamp on all three SK channel subtypes, resulting in similar IC50 of 0.4µM. We also
assessed the selectivity of BBP on a panel of calcium-activated and voltage-activated
potassium channels using two-electrode voltage clamp, automatic and manual patch
clamp. BBP did not have any effect on IK, Kir2.1, Kir3.1+Kir3.4, Kv1.5, Kv4.3/KCHIP2
and Kv7.1/KCNE1 currents and was 4.8-fold and 46-fold more potent on all SK channel
subtypes vs. BK and hERG channels, respectively. Moreover, we were able to identify
H491 as a critical amino acid for the pharmacological effect of BBP on the SK channel.
From a medicinal chemistry perspective, BBP could be used as a starting point for the
design of new and improved SK inhibitors.
Keywords: small conductance calcium-activated potassium channels, SK channels, KCa2, BBP,
2,6-bis(2-benzimidazolyl)pyridine, polycyclic pyridine, blocker
INTRODUCTION
Small conductance calcium-activated potassium (SK) channels are ion channels that open when the
intracellular calcium concentration is increased, allowing the passage of potassium ions through cell
membrane. These submicromolar changes in the intracellular calcium concentration are sensed by
the protein calmodulin, which is covalently attached to the C-terminus of the channel (Adelman,
2016). The SK channel is now considered a promising novel target in a wide range of therapeutic
areas such as cardiovascular (Gu et al., 2018), neurology (Kshatri et al., 2018), and oncology
(Berthe et al., 2016). This interest has prompted the development of new molecules to both study
and therapeutically target these channels. Since the discovery of apamin, a neurotoxin extracted
from bee venom and the first specific SK inhibitor described (Habermann, 1984), the lists of
both SK channel activators and inhibitors have grown (Weatherall et al., 2010; Christophersen
and Wulff, 2015), including most recently the negative allosteric modulator AP14145
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(Diness et al., 2017; Simó-Vicens et al., 2017a) and the natural
flavone acacetin (Chen et al., 2017). However, some of these
compounds may be difficult to access and/or use for a number
of reasons such as low potency, incomplete pharmacological
characterization or commercial unavailability.
In 2005, a patent application was filed proposing a variety
of polycyclic pyridines as structurally related to neuromuscular
inhibitors such as tubocurarine, pancuronium, and atracurium,
and as having inhibitory effect on the SK channel, similarly to
UCL compounds (Campos Rosa et al., 2000; Wang et al., 2005),
a series of non-peptidic and potent SK inhibitors represented
by UCL1684 (Figure 1). This patent includes N-(pyridin-2-
yl)-4-(pyridin-2-yl)thiazol-2-amine (ICA, Figure 1), an apamin-
displacing 2-aminothiazole (Gentles et al., 2008), which has not
only proven to be a highly specific and potent inhibitor of SK
channels but has also been successfully used in multiple studies
as an antiarrhythmic agent (Diness et al., 2010; Skibsbye et al.,
2014). The patent further describes a class of 2-benzimidazolyl
pyridines, including 2,6-bis(2-benzimidazolyl)pyridine (BBP,
Figure 1), a small organic compound which has in literature
been described in a broad range of other chemical and biological
uses, including as a chemosensor to detect toxic metabolites
(Chetia and Iyer, 2006, 2007, 2008, 2011), as chemical catalyst
in organic chemistry (Dai et al., 2017; Renuka and Gayathri,
2018) and as having pharmacological effects as potential antiviral
(Musiu et al., 2014) and anticancer agent (Zheng et al., 2017).
Most of these applications rely on the ability of BBP to mimic
the biological histidine-imidazole system which can bind and
accommodate metals and a number of organic molecules.
Unfortunately, BBP was in the above patent application only
generally described amongst many other compounds as an SK
inhibitor without disclosing a specific IC50 and has never been
properly pharmacologically characterized. Since BBP represents
a readily available and interesting chemical scaffold for the
development of new and improved SK inhibitors, we in this work
aimed to thoroughly characterize and describe the potency and
selectivity of BBP as an SK channel inhibitor.
Through different electrophysiological techniques, we have
assessed the inhibitory potency of BBP on all three SK channel
subtypes, as well as its selectivity on a panel of calcium-activated
and voltage-activated potassium channels. Moreover, through
mutagenesis studies, we have been able to identify the putative
binding site of BBP.
MATERIALS AND METHODS
Molecular Biology
rSK3 H491N was obtained through site-directed mutagenesis
on the rSK3 WT gene (Department of Biomedical Sciences,
Copenhagen, Denmark). This was achieved using the forward
primer GAGTCTGTGAAAGGTACAATGACCAGCAGGACG
and reverse primer CGTCCTGCTGGTCATTGTACCTTTCAC
AGACTC with the DNA polymerase PfuI Ultra II Fusion
(Agilent, Santa Clara, California, United States). The resulting
product was then used to transform competent Escherichia coli
by thermic shock, which were plated on agar plates containing
the corresponding selection antibiotic and incubated overnight
at 37◦C. The next day, plasmid DNA was purified using standard
methods and sent for sequencing to verify the construct.
HEK293 cells were transiently co-transfected with the plasmid
of interest (hBK, hSK1, hSK2, hSK3 WT, rSK3 H491N, or hIK)
and eGFP using standard LipofectamineTM 2000 (Thermo Fisher
Scientific,Waltham,Massachussets, USA) transfection protocols.
After transfection, cells were incubated overnight before the
experiments.
Cell Lines Culture
Three different stable HEK293 cell lines expressing hSK1, hSK2
or hSK3 (NeuroSearch A/S, Ballerup, Denmark) and a CHO
stable cell line expressing hERG (University of Copenhagen,
Copenhagen, Denmark) were used for automated patch clamp.
These cells were cultivated and prepared as previously described
(Skarsfeldt et al., 2016).
WT HEK293 cells used for transient transfections were
cultured in the same way as HEK293 stable cell lines in the
absence of the selection antibiotic geneticin.
Chemicals
2,6-Bis(2-benzimidazolyl)pyridine (BBP), dofetilide, bicuculline
methiodide, paxilline, 1-[(2-chlorophenyl)diphenylmethyl]-
1H-pyrazole (TRAM-34) and 4-aminopyridine were purchased
from Sigma-Aldrich (Germany). 2-(4-Chlorophenoxy)-2-
methyl-N-[5-[(methylsulfonyl)amino]tricyclo[3.3.1.13,7]dec-
2-yl]-propanamide (JNJ 303) was purchased from
Tocris (United Kingdom) and N-(2-{[(1R)-1-[3-
(trifluoromethyl)phenyl]ethyl]amino}-1H-1,3-benzodiazol-
4-yl)acetamide (AP14145) was synthetized by Syngene Inc.
(Bangalore, India). All compounds were dissolved in pure
dimethyl sulfoxide (Sigma-Aldrich, Germany) into 10mM stock
solutions and stored at −20◦C. On the day of the experiment,
the stock solution was thawed and the corresponding amount of
compound was added to the working solution.
Electrophysiology
Automated Patch-Clamp
Automated patch clamp (QPatch 16, Sophion, Denmark) on
SK-expressing HEK293 cell lines was conducted as previously
described (Simó-Vicens et al., 2017b). Briefly, SK currents were
elicited by voltage-ramps starting at −80mV and finishing at
+80mV from a holding potential of 0mV. Extracellular solution
contained 0.1mM CaCl2, 3mM MgCl2, 154mM KCl, 10mM
HEPES and 10mM glucose with pH 7.4. Intracellular solution for
SK experiments contained 8.106mM CaCl2 (final free calcium
concentration of 400 nM), 1.167mM MgCl2, 10mM EGTA,
154mM KCl, 10mM HEPES, 31.25/ 10mM KOH/EGTA and
15mM KOH with pH 7.2. Automated patch clamp on hERG-
expressing CHO cell line was performed also as previously
described (Skarsfeldt et al., 2016).
Manual Patch-Clamp
Manual patch clamp experiments were performed at room
temperature in the whole cell configuration with a HEKA
EPC9 amplifier and the Patchmaster software (HEKA Elektronik,
Ludwigshafen, Germany). All currents were elicited every 2 s
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FIGURE 1 | Chemical structures of SK blockers UCL1684 and ICA, SK negative allosteric modulator AP14145, and BBP.
using an incremental 200ms voltage-ramp protocol starting at
−80mV and finishing at +80mV from a holding potential
of 0mV. Borosilicate glass pipettes were pulled with a
horizontal puller (DMZ Universal Puller, Zeitz Instruments,
Martinsried, Germany) with resistances 2.5–3 M. Currents
were measured using the same solutions as the ones used
for automated patch clamp, with symmetrical potassium
concentrations and a free intracellular calcium concentration
of 400 nM. In hBK experiments, intracellular solution was
modified as previously described (Strøbæk et al., 2006) and free
intracellular calcium concentration was reduced to 100 nM. On
the day of the experiment, cells were rinsed with magnesium-
free PBS and detached with DetachinTM (Amsbio, Abingdon,
United Kingdom) before being plated on 0.5mm diameter
coverslips. Only fluorescent cells were considered for patch clamp
experiments.
Two-Electrode Voltage Clamp (TEVC)
cRNA was prepared from linearized plasmids using the
mMESSAGE mMACHINE T7 kit (Ambion, USA) and
quantified by UV spectroscopy (NanoDrop, Thermo Scientific,
Wilmington, USA). Xenopus laevis oocytes were acquired from
EcoCyte Bioscience (Castrop-Rauxel, Germany). Oocytes were
injected with 50 nL cRNA and currents were recorded after
2 days of incubation at 19◦C. Currents were recorded at a
sampling rate of 10 kHz using a TEVC amplifier (Dagan CA-1B;
IL, USA), and borosilicate glass recording electrodes (Module
Ohm, Herlev, Denmark), made with a DMZ Universal Puller
(Zeitz Instruments, Martinsried, Germany) with a resistance of
0.5–1 M when filled with 2M KCl. Oocytes were superfused
with Kulori (pH 7.4) solution containing NaCl 90mM, KCl
4mM, MgCl2 1mM, CaCl2 1mM, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 5mM, and currents were elicited
with the voltage protocols previously indicated (Skarsfeldt et al.,
2016), from a holding potential of−80mV. Data acquisition was
performed with the Patchmaster software (HEKA Elektronik,
Ludwigshafen, Germany).
Data Analysis
All data were analyzed using GraphPad Prism 7 and results are
presented as mean ± SEM. Statistical differences are considered
significant when p< 0.05. n refers to the number of cells that have
been tested for each experiment.
Individual IC50 values were calculated for each cell with






Where Y is the normalized response, from 100, corresponding
to current recorded during saline perfusion, down to 0,
corresponding to currents recorded in the presence of bicuculline
methiodide 100µM. X is the log of the BBP concentration. A
standard Hill Slope of −1 was considered for this purpose. The
resulting IC50 were then used in one-way ANOVA statistical
analysis to detect potential subtype selectivity among hSK1,
hSK2, and hSK3. Finally, individual IC50 values were used to
calculate the total mean± SEM.
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To assess the effect of BBP on other calcium-activated
potassium channels (hBK, hSK3 WT, rSK3 H491N, and hIK),
each individual current was first normalized to its cell size
using membrane’s capacitance (pA/pF) before statistical analysis.
For the rest of voltage-activated potassium channels (Kir2.1,
Kir3.1+Kir3.4, Kv1.5, Kv4.3/KCHIP2, Kv7.1/KCNE1 and hERG),
raw data from current measurements were directly used for
statistical analysis. Statistical significance between saline and the
effect of both BBP and the corresponding reference compound
was determined for each channel using one-way ANOVA
analysis. To compare the effect of BBP on hSK3 WT and
rSK3 H491N, individual raw data for each cell were first
normalized. In this case, currents elicited under saline perfusion
were considered as full channel activation and currents elicited
with the presence of either bicuculline methiodide (100µM) or
AP14145 (10µM) were considered as full channel inhibition.
Later, the resulting data were compared using unpaired t-test to
determine statistically significant differences of inhibitory effect
of BBP between the WT and mutant channels. For graphic
and comparative purposes in Figure 5, corresponding raw data
were normalized using current values under saline perfusion as
fully activated and the value 0 as fully inhibited currents. These
normalized data were not used in statistical analysis.
RESULTS
BBP Inhibits All SK Channel Subtypes With
Similar Potency
To assess the in vitro potency and potentially subtype selectivity
of BBP, we used the automated patch clamp platform QPatch
16. These experiments were conducted on the whole cell
configuration, using three different stable HEK cell lines
expressing hSK1, hSK2, or hSK3. During the experiments, each
cell was exposed to six increasing concentrations of BBP, starting
at 10 nM and up to 3µM. In the end, bicuculline methiodide
100µM, which was used as positive control and reference, was
added. All three hSK subtypes were inhibited by BBP. hSK
currents were inhibited in a dose-dependent manner, starting at
submicromolar concentrations and reaching total inhibition at
3µM (Figures 2A,B). These data were used to calculate BBP IC50
on each of the hSK channel subtypes resulting in 0.7 ± 0.2µM
for hSK1 (n = 9), 0.4 ± 0.1µM for hSK2 (n = 8) and 0.4 ±
0.2µM for hSK3 (n = 9, Figure 2C). No significant statistical
differences were found between IC50 values, suggesting that BBP
is equipotent on all SK subtypes.
Effect of BBP on Other Calcium-Activated
Potassium Channels
After testing BBP on the three SK channel subtypes, we decided
to explore whether other calcium-activated potassium channels
were affected by the compound. To do so, we transiently
transfected HEK293 WT cells with a plasmid containing one
of the human SK channel subtypes, the big conductance
calcium and voltage-activated potassium (BK) channel or the
intermediate conductance calcium-activated potassium (IK)
channel. These cells were plated on glass coverslips and used for
FIGURE 2 | Inhibitory effect of BBP on hSK channels. Representative
current-time plot (A) and its corresponding current-voltage plot (B) from
automated patch clamp experiments picturing the inhibitory effect of BBP at
different increasing concentrations performed on hSK3-expressing cells. The
compound completely inhibited SK currents at concentrations of 1–3µM. (C)
Depicts the inhibition curves of BBP on each of the hSK subtype channels
Resulting IC50 were 0.7 ± 0.2µM for hSK1 (n = 9), 0.4 ± 0.1µM for hSK2
(n = 8) and 0.4 ± 0.2µM for hSK3 (n = 9).
whole cell manual patch clamp experiments. The cells were first
perfused with saline solution until a stable baseline was reached.
The solution in the bath was thereafter changed, and the cells
were exposed to BBP (1µM)whichwas perfused for at least 2min
or until full effect of the drug was reached. Finally, a positive
control was used to inhibit the remaining current and quantify
the total effect of BBP. Both hBK and hIK currents were elicited
with the same voltage ramp protocol as the one described for hSK
currents.
First, we wanted to confirm that 1µM BBP was sufficient
to completely block all SK channel subtypes on the manual
patch clamp setup. BBP 1µM inhibited 93.7 ± 1.6% of hSK1
current (n = 6), 94.8 ± 2.1% of hSK2 current (n = 5), and
92.5 ± 2.3% of hSK3 current (n = 5) when compared to the
positive control bicuculline methiodide (100µM). These results
confirm the equipotency of BBP among all SK channel subtypes
as previously observed on the automated patch clamp. Moreover,
in order to assess possible voltage-dependent inhibition of BBP,
we compared its effect at −80 and +80mV. Statistical analyses
showed no significant differences between inhibition at −80 or
+80mV.
When BBP (1µM) was applied on HEK293 cells transfected
with hIK, the elicited current remained unaffected (n = 6,
Figures 3A,B). The same IK current was completely inhibited
by the specific blocker TRAM-34 1µM (Wulff et al., 2000,
Figure 3C). In contrast, hBK transfected cells were only partially
but significantly inhibited by BBP 1µM (n = 8, Figures 4A,B).
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FIGURE 3 | Effect of BBP 1µM on hIK (n = 6). Representative current-time
plot (A) and its corresponding current-voltage plot (B) depicting the effect of
BBP 1µM and the specific IK inhibitor TRAM-34 1µM. (C), a column graph
compares the effects of both BBP and TRAM-34 with the control current. IK
current was not affected by BBP 1µM. *p < 0.05.
Inhibition by BBP resulted in a 19 ± 6% reduction of the hBK
current. The remaining current was totally inhibited after the cell
was exposed to paxilline 3µM (Figure 4C), a specific negative BK
channel modulator (Sanchez and McManus, 1996).
The inhibitory effect of BBP 1µM on all calcium-activated
potassium channels has been combined in Figure 5.
Effect of BBP on Other Potassium
Channels
To complete the selectivity profile of BBP, we tested the drug on
the following potassium channels: inward rectifying potassium
channels Kir2.1 and Kir3.1+Kir3.4, voltage-gated potassium
channels Kv1.5, Kv4.3/KCHIP2 and Kv7.1/KCNE1 and the
FIGURE 4 | Effect of BBP 1µM on hBK (n = 8). Representative current-time
plot (A) and its corresponding current-voltage plot (B) depicting the effect of
BBP 1µM and the specific BK inhibitor paxilline 3µM. The column graph (C)
compares the effects of both BBP and paxilline with the control current. BK
current was inhibited by 19 ± 6% upon application of BBP 1µM. *p < 0.05.
ether-à-go-go-related-gene potassium channel hERG. Except for
hERG, all channels were expressed in oocytes fromXenopus laevis
previously injected with the corresponding cRNA. Two days after
the injection, the oocytes were ready for TEVC experiments.
First, the oocytes were perfused with Kulori solution. After
3min, when stable current levels were achieved, the solution was
changed to a Kulori solution containing BBP 10µM and the
oocyte superfused for 3 additionalminutes or until full drug effect
was achieved. Finally, the remaining current was inhibited with
a reference inhibitor used as positive control: Ba2+ 100µM for
Kir2.1, terteapine-Q 1µM for Kir3.1+Kir3.4, 4-aminopyridine
4mM for both Kv1.5 and Kv4.3/KCHIP2, and finally JNJ303
1µM for Kv7.1/KCNE1. Application of BBP 10µM did not
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FIGURE 5 | Column graph comparing the inhibitory effect of BBP 1µM
measured on the manual patch clamp on all calcium-activated potassium
channels: SK1 (n = 6), SK2 (n = 5), SK3 (n = 5), IK (n = 6) and BK (n = 8)
channels. BBP 1µM totally inhibited all SK currents as well as 19 ± 6% of BK
current. However, the IK channel was not affected by BBP 1µM.
FIGURE 6 | Column graph comparing the inhibitory effect of BBP 10µM on a
panel of voltage-gated potassium channels (n = 5 for each current). Except
hERG, none of the tested currents were significantly affected by the
compound.
significantly affect any of the aforementioned currents (n= 5 for
each current, Figure 6).
Effects on hERG were tested using automated patch clamp on
a stable CHO cell line expressing the hERG channel. In this case,
we used dofetilide 500 nM as reference. This time, when cells
were exposed to BBP 10µM, hERG current was reduced by 19
± 3% (n= 5, Figure 6).
H491 Is Critical for BBP Inhibition on rSK3
In an attempt to elucidate possible binding determinants for
BBP, we decided to test the drug on the apamin-insensitive rSK3
H491N mutant, an amino acid located at the extracellular loop
between S5 and the P-loop of the channel (Lamy et al., 2010). To
this end, we transiently transfected HEK cells with rSK3 H491N
mutant and used these to perform whole cell manual patch clamp
experiments. Again, currents were elicited by voltage ramps
ranging from −80 to +80mV, from a holding potential of 0mV,
and channels were activated with 400 nM of free intracellular
calcium. Once the mutant SK current was stable, BBP 1µM was
applied on the cell for at least 2min or until the drug reached
its total effect. At the end of the experiment, AP14145 10µM
was added to the bath and used as reference. Surprisingly, and
in contrast to hSK3 WT (Figure 7A), rSK3 H491N current was
not inhibited by BBP 1µM (n = 8), but it was slightly increased
in the presence of the drug (Figures 7B,C).
DISCUSSION
SK channels have gained increasing interest during recent
years, being considered as promising therapeutic targets for
multiple diseases through a wide spectrum of therapeutic areas
(Berthe et al., 2016; Gu et al., 2018; Kshatri et al., 2018).
Since the discovery of the first specific SK inhibitor, apamin
(Habermann, 1984), research efforts have been invested in the
development and discovery of new molecules targeting SK
channels. This has resulted in a gradually and expanding list of
both SK inhibitors and activators, ranging from synthetic and
natural peptides to small molecules of a variety of chemical
classes and including different mechanisms of action (Weatherall
et al., 2010; Christophersen and Wulff, 2015). Despite this
progress, many of the disclosed molecules may not be suitable
as practical tool compounds for the study of SK channels.
From an accessibility perspective these compounds may not be
commercially available and only achievable in small amounts.
In addition, compounds may not be pharmacologically well
characterized and with sufficient SK channel potency or general
selectivity. Moreover, expansion of SK channels research, has
further challenged currently available pharmacological tools
which have been confronted with insensitive heteromeric
channels (Hancock et al., 2015), difficult to access intracellular
locations (Krabbendam et al., 2018), unexpected inhibitory
effects (Voos et al., 2017), and intracellular calcium dependence
(Strøbæk et al., 2006; Simó-Vicens et al., 2017a).
In the past, a series of 2-benzimidazolyl pyridines, including
2,6-bis(2-benzimidazolyl)pyridine (BBP), were claimed in a
patent as being SK channel inhibitors (Wang et al., 2005). As
the pharmacological data disclosed was very general we decided
to characterize BBP on our automated patch clamp platform to
assess its potency on all SK channel subtypes. These experiments
revealed that BBP was able to inhibit the three SK channel
subtypes at submicromolar concentrations (Figures 2A,B), with
similar potency and an IC50 of ∼0.4µM (Figure 2C). Because
BBP is an interesting and versatile chemical scaffold we thought
that it could be potentially used as a new starting building
block for the development of new and improved SK blockers.
We therefore expanded the pharmacological characterization
and assessed the selectivity of BBP over a panel of calcium
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FIGURE 7 | Effect of BBP 1µM on hSK3 WT (n = 5) and rSK3 H491N (n = 8). Representative current-time plots (left) and their corresponding current-voltage plots
(right) depicting the effect of BBP 1µM on hSK3 WT (A) and rSK3 H491N (B). The results are summarized in the column graph (C) comparing the effect of the
compound on both the WT and mutant channel. The mutant rSK3 H491N channel was insensitive to the inhibitory effect of BBP compared to the WT channel.
*p < 0.05.
and voltage-activated potassium channels. Within the calcium-
activated potassium channels, it was found that the IK channel
was not affected by BBP 1µM (Figures 3A,B) whereas BK
channel was inhibited by 19 ± 6% (Figure 4C), an inhibitory
effect 4.8-fold lower than on any SK currents. Interestingly, this
relation between BK and SK channels has also been observed
for the allosteric modulator AP14145 (Simó-Vicens et al., 2017a).
In the case of voltage-activated potassium channels, none of the
six tested currents (Kir2.1, Kir3.1+Kir3.4, Kv1.5, Kv4.3/KCHIP2,
Kv7.1/KCNE1, hERG) were significantly affected by BBP 10µM,
except for hERG, which was reduced by 19 ± 3% (Figure 6).
Although the present work shows a promising selectivity profile
of BBP over eight calcium and voltage-activated potassium
channels, further selectivity profiling over different ion channels
and proteins as well as pharmacokinetic assessments will be
needed to determine the suitability of BBP for each specific
application.
In addition to the pharmacological profiling, and to get a
better understanding of the mechanism of action of BBP on the
SK channel, we conducted a study to possibly identify important
molecular determinants for BBP throughmutagenesis studies. To
this end, we used the rSK3 H491N mutant which is known to
be insensitive to apamin, D-tubocurarine and UCL1684 (Lamy
et al., 2010), all being potent SK channel blockers. Interestingly,
the inhibitory effect of BBP was completely abolished by the
mutation (Figure 6B), suggesting that the compound binds to
the extracellular loop between S5 and the P-loop of the channel,
sharing its binding site with apamin. In contrast to the allosteric
SK channel modulators NS8593 (Strøbæk et al., 2006; Jenkins
et al., 2011) and AP14145 (Simó-Vicens et al., 2017a), BBP
thus appears to have common mechanism with compounds
earlier claimed to block the pore of the ion channel, such as
UCL1684 and ICA. Here it is interesting to note that the patent
mentioning ICA and BBP (Wang et al., 2005) also describes
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this class of compounds as having ability to form a complex
with polyvalent metal cations. This is suggested as a tridentate
interaction between the metal cation and three nitrogen atoms
comprised in the core and the connected heterocycles of the SK
inhibitor, in BBP being the central pyridine and a nitrogen of
each of the two benzimidazole moieties (Figure 1). Any presence
or influence of such metal complex in the mechanism-of-action
of BBP and ICA has not been studied or described to date and
further studies are needed to fully understand the mechanism
of action of this class of SK inhibitors and its relation to other
described inhibitors.
In summary, BBP is a potent and selective SK inhibitor
with pharmacological action critically depending on interaction
with histidine residue H491. BBP is readily available and
together with the herein described selective profile we
envision that it can become a new versatile and interesting
starting block for the development of future SK channel
blockers.
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